173 related articles for article (PubMed ID: 35895075)
1. Clinical and demographic factors contributing to asparaginase-associated toxicities in children with acute lymphoblastic leukemia.
Dharia P; Swartz MD; Bernhardt MB; Chen H; Gramatges MM; Lupo PJ; Brown AL; Scheurer ME
Leuk Lymphoma; 2022 Dec; 63(12):2948-2954. PubMed ID: 35895075
[TBL] [Abstract][Full Text] [Related]
2. Asparaginase Toxicities: Identification and Management in Patients With Acute Lymphoblastic Leukemia
.
Thu Huynh V; Bergeron S
Clin J Oncol Nurs; 2017 Oct; 21(5):E248-E259. PubMed ID: 28945721
[TBL] [Abstract][Full Text] [Related]
3. The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.
Horvat TZ; Pecoraro JJ; Daley RJ; Buie LW; King AC; Rampal RK; Tallman MS; Park JH; Douer D
Leuk Res; 2016 Nov; 50():17-20. PubMed ID: 27631159
[TBL] [Abstract][Full Text] [Related]
4. Intermittent Versus Continuous PEG-Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study.
Albertsen BK; Grell K; Abrahamsson J; Lund B; Vettenranta K; Jónsson ÓG; Frandsen TL; Wolthers BO; Heyman M; Schmiegelow K
J Clin Oncol; 2019 Jul; 37(19):1638-1646. PubMed ID: 30978155
[TBL] [Abstract][Full Text] [Related]
5. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia.
Aldoss I; Douer D; Behrendt CE; Chaudhary P; Mohrbacher A; Vrona J; Pullarkat V
Eur J Haematol; 2016 Apr; 96(4):375-80. PubMed ID: 26095294
[TBL] [Abstract][Full Text] [Related]
6. Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol.
Raja RA; Schmiegelow K; Albertsen BK; Prunsild K; Zeller B; Vaitkeviciene G; Abrahamsson J; Heyman M; Taskinen M; Harila-Saari A; Kanerva J; Frandsen TL;
Br J Haematol; 2014 Apr; 165(1):126-33. PubMed ID: 24428625
[TBL] [Abstract][Full Text] [Related]
7. Tolerability and toxicity of pegaspargase in adults 40 years and older with acute lymphoblastic leukemia.
Daley RJ; Rajeeve S; Kabel CC; Pappacena JJ; Stump SE; Lavery JA; Tallman MS; Geyer MB; Park JH
Leuk Lymphoma; 2021 Jan; 62(1):176-184. PubMed ID: 32985296
[TBL] [Abstract][Full Text] [Related]
8. Trypsin-encoding
Wolthers BO; Frandsen TL; Patel CJ; Abaji R; Attarbaschi A; Barzilai S; Colombini A; Escherich G; Grosjean M; Krajinovic M; Larsen E; Liang DC; Möricke A; Rasmussen KK; Samarasinghe S; Silverman LB; van der Sluis IM; Stanulla M; Tulstrup M; Yadav R; Yang W; Zapotocka E; Gupta R; Schmiegelow K;
Haematologica; 2019 Mar; 104(3):556-563. PubMed ID: 30467200
[TBL] [Abstract][Full Text] [Related]
9. Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age.
Rank CU; Wolthers BO; Grell K; Albertsen BK; Frandsen TL; Overgaard UM; Toft N; Nielsen OJ; Wehner PS; Harila-Saari A; Heyman MM; Malmros J; Abrahamsson J; Norén-Nyström U; Tomaszewska-Toporska B; Lund B; Jarvis KB; Quist-Paulsen P; Vaitkevičienė GE; Griškevičius L; Taskinen M; Wartiovaara-Kautto U; Lepik K; Punab M; Jónsson ÓG; Schmiegelow K
J Clin Oncol; 2020 Jan; 38(2):145-154. PubMed ID: 31770057
[TBL] [Abstract][Full Text] [Related]
10. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
[TBL] [Abstract][Full Text] [Related]
11. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia.
Douer D; Aldoss I; Lunning MA; Burke PW; Ramezani L; Mark L; Vrona J; Park JH; Tallman MS; Avramis VI; Pullarkat V; Mohrbacher AM
J Clin Oncol; 2014 Mar; 32(9):905-11. PubMed ID: 24516026
[TBL] [Abstract][Full Text] [Related]
13. PEGylated
Verma A; Chen K; Bender C; Gorney N; Leonard W; Barnette P
Pediatr Hematol Oncol; 2019 Aug; 36(5):277-286. PubMed ID: 31296092
[TBL] [Abstract][Full Text] [Related]
14. Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study.
Wolthers BO; Frandsen TL; Baruchel A; Attarbaschi A; Barzilai S; Colombini A; Escherich G; Grell K; Inaba H; Kovacs G; Liang DC; Mateos M; Mondelaers V; Möricke A; Ociepa T; Samarasinghe S; Silverman LB; van der Sluis IM; Stanulla M; Vrooman LM; Yano M; Zapotocka E; Schmiegelow K;
Lancet Oncol; 2017 Sep; 18(9):1238-1248. PubMed ID: 28736188
[TBL] [Abstract][Full Text] [Related]
15. Antithrombin supplementation did not impact the incidence of pegylated asparaginase-induced venous thromboembolism in adults with acute lymphoblastic leukemia.
Chen J; Ngo D; Aldoss I; Shayani S; Tsai NC; Pullarkat V
Leuk Lymphoma; 2019 May; 60(5):1187-1192. PubMed ID: 30322332
[TBL] [Abstract][Full Text] [Related]
16. Asparaginase-associated toxicity in children with acute lymphoblastic leukemia.
Hijiya N; van der Sluis IM
Leuk Lymphoma; 2016; 57(4):748-57. PubMed ID: 26457414
[TBL] [Abstract][Full Text] [Related]
17. Pegaspargase-induced hypertriglyceridemia in a patient with acute lymphoblastic leukemia.
Lau KM; Saunders IM; Goodman A
J Oncol Pharm Pract; 2020 Jan; 26(1):193-199. PubMed ID: 30823860
[TBL] [Abstract][Full Text] [Related]
18. Pegaspargase-induced pancreatitis.
Alvarez OA; Zimmerman G
Med Pediatr Oncol; 2000 Mar; 34(3):200-5. PubMed ID: 10696127
[TBL] [Abstract][Full Text] [Related]
19. Asparaginase enzyme activity levels and toxicity in childhood acute lymphoblastic leukemia: a NOPHO ALL2008 study.
Lynggaard LS; Rank CU; Hansen SN; Gottschalk Højfeldt S; Henriksen LT; Jarvis KB; Ranta S; Niinimäki R; Harila-Saari A; Wolthers BO; Frandsen TL; Heyman M; Schmiegelow K; Albertsen BK
Blood Adv; 2022 Jan; 6(1):138-147. PubMed ID: 34625787
[TBL] [Abstract][Full Text] [Related]
20. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
